Ashley Teusink-Cross
Overview
Explore the profile of Ashley Teusink-Cross including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mizuno K, Dandoy C, Teusink-Cross A, Davies S, Vinks A, Jodele S
Blood Adv
. 2022 Jan;
6(5):1454-1463.
PMID: 35008105
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal posttransplant complication of hematopoietic stem cell transplantation. We recently reported that survival for TA-TMA has been improved by early intervention with eculizumab, a...
12.
Gardner J, Courter J, Dandoy C, Davies S, Teusink-Cross A
Transplant Cell Ther
. 2021 Dec;
28(3):167.e1-167.e5.
PMID: 34875405
Levofloxacin has been widely used for bacteremia prophylaxis in the pre-engraftment setting for patients undergoing hematopoietic stem cell transplantation (HSCT), but data supporting this practice are inconsistent. In addition to...
13.
Edwards A, Teusink-Cross A, Martin L, Prows C, Mehta P, Ramsey L
Clin Transl Sci
. 2021 Oct;
15(3):610-618.
PMID: 34670017
Chemotherapy-induced nausea and vomiting (CINV) is commonly experienced by patients receiving antineoplastic agents prior to hemopoietic stem cell transplant (HSCT). Ondansetron, a 5-HT3 antagonist metabolized by CYP2D6, is an antiemetic...
14.
Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure
Sabulski A, Myers K, Bleesing J, Duell A, Lane A, Teusink-Cross A, et al.
Blood Adv
. 2021 Oct;
5(22):4594-4604.
PMID: 34614507
Graft rejection (GR) is a poorly understood complication of hematopoietic cell transplant (HCT). GR risk factors are well published, but there are no reliable biomarkers or therapies known. Fever is...
15.
Arnold D, Emoto C, Fukuda T, Dong M, Vinks A, Lane A, et al.
Bone Marrow Transplant
. 2021 Sep;
56(12):3029-3031.
PMID: 34548626
Alemtuzumab is used as part of reduced-intensity and reduced-toxicity transplant conditioning regimens for nonmalignant diseases. Prior studies identified an ideal target concentration range of 0.15-0.6 mcg/mL at day 0. However,...
16.
Koo J, Teusink-Cross A, Davies S, Jodele S, Dandoy C
Pediatr Blood Cancer
. 2021 Sep;
68(11):e29319.
PMID: 34490994
Background: High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is an established treatment for pediatric and young adult patients with solid tumors and lymphomas. Plerixafor is a CXC chemokine...
17.
Khandelwal P, Teusink-Cross A, Kumar A, Bleesing J, Mehta P, Jordan M, et al.
Br J Haematol
. 2021 May;
194(5):e84-e89.
PMID: 34046889
No abstract available.
18.
Hughes K, Garrity L, Nelson A, Lane A, Teusink-Cross A
Pediatr Transplant
. 2021 Apr;
25(4):e14026.
PMID: 33894096
Introduction: Busulfan is a chemotherapy agent used in hematopoietic stem cell transplant (HSCT) conditioning regimens. Busulfan is associated with tonic-clonic seizures in ~10% of patients if administered without seizure prophylaxis....
19.
Wang Y, Teusink-Cross A, Elborai Y, Krupski M, Nelson A, Grimley M, et al.
Transplantation
. 2021 Apr;
106(2):412-419.
PMID: 33795598
Background: Ruxolitinib, a JAK1/2 inhibitor, is used to treat chronic graft versus host disease (cGVHD) in adult allogeneic hematopoietic stem cell transplant patients, but experience in children is limited, perhaps...
20.
Wallace G, Khandelwal P, Myers K, Perentesis E, Lane A, Teusink-Cross A, et al.
Bone Marrow Transplant
. 2021 Jan;
56(6):1441-1444.
PMID: 33420390
Skin graft versus host disease (GVHD) can affect quality of life in hematopoietic stem cell transplant recipients. Therapeutic options for steroid-refractory GVHD are limited. We report the first prospective pilot...